Epidemiological and Probabilistic Assessment of Chronic Morbidity Induced by Patient Nondisclosure and Deception

The Epistemological Blind Spot in Diagnostic Safety

Quantifying the exact incidence of chronic disease caused by patients withholding, distorting, or fabricating clinical information represents one of the most persistent analytical challenges in modern epidemiology. While diagnostic errors affect approximately 12 million U.S. adults in outpatient settings annually¹ and account for nearly 795,000 deaths or cases of permanent disability each year², global health registries and administrative claims databases contain virtually no direct metrics attributing chronic morbidity to patient deception. This absence of documentation does not reflect a rarity of the phenomenon; rather, it is an artifact of how clinical medicine classifies diagnostic breakdowns, how regulatory frameworks govern electronic health records (EHRs), and how unsolved pathologies are assigned to "idiopathic" or "cryptogenic" categories³.

In classical diagnostic safety taxonomies—most notably the Diagnostic Error Evaluation and Research (DEER) taxonomy and the Safer Dx framework—analytic focus has historically centered on clinician cognitive biases, such as premature closure, anchoring, and confirmation bias, alongside health system fragmentation⁴. However, empirical audits of primary care diagnostic errors reveal that 78.9% of all process breakdowns originate directly within the patient-practitioner clinical encounter⁵. Within these encounter failures, 56.3% involve defects in history-taking, 47.4% involve physical examination inadequacies, and 57.4% involve errors in ordering diagnostic tests, while 16.3% are explicitly categorized as patient-related factors, such as providing misleading information or failing to adhere to follow-up⁵. When diagnostic failures escalate into hospital-reported serious adverse events (SAEs)—where 31.2% result in patient death and 22.9% result in permanent disability—retrospective analyses using the Eindhoven Classification Model demonstrate that patient-related factors are present in 73.4% of all cases³. Crucially, clinical reviewers almost never code these events as patient deception; instead, they are absorbed into clinical categories such as "atypical clinical presentation" (33.9%) or masking "comorbidity" (20.2%)³. In neurological conditions such as optic neuritis, failures in eliciting or interpreting critical elements of the patient history alone account for one-third of all missed or delayed diagnoses⁶.

Beyond taxonomic absorption, structural forces in regulatory policy and medical coding actively suppress the clinical documentation of patient dishonesty. The implementation of the 21st Century Cures Act final rule in April 2021 mandated immediate, barrier-free patient access to clinical notes ("Open Notes") across the United States, with narrow exceptions limited to psychotherapy process notes or imminent physical harm⁷. Because patients routinely review their medical charts, risk management foundations and medical educators explicitly instruct clinicians to eliminate terms that imply dishonesty, distrust, or judgment⁸. Clinicians are advised to replace "noncompliance" with neutral descriptions of behavior, avoid importing unverified social or substance use histories, and refrain from recording unconfirmed suspicions of fabrication to prevent patient conflict, record-amendment disputes, and malpractice litigation⁸.

Concurrently, administrative coding constraints within the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) reinforce this documentation gap. Codes designated for treatment and medication nonadherence (Z91.1 through Z91.19) impose strict clinical validation thresholds⁹. To assign billable codes such as Z91.120 (intentional underdosing of medication regimen due to financial hardship) or Z91.130 (unintentional underdosing due to age-related debility or cognitive limitations), coding guidelines require explicit patient statements confirming the behavior alongside corroborating pharmacy refill logs⁹. General noncompliance (Z91.19) is designated as a non-billable parent code that cannot be used for reimbursement purposes¹⁰. Consequently, when a patient surreptitiously halts therapy or conceals toxin exposure while claiming adherence, the resulting organ damage is coded solely under its terminal pathological manifestation, such as end-stage renal disease or heart failure, severing the causal link in epidemiological surveillance.

Empirical Baseline of Patient Nondisclosure and Deception

While clinical charts rarely record patient deception, anonymized population-level behavioral surveys demonstrate that withholding or distorting medically relevant information is the normative baseline in healthcare interactions¹¹. Across two national U.S. online surveys totaling 4,510 adults—an Amazon Mechanical Turk (MTurk) cohort of 2,011 younger adults (mean age 36 years) and a Survey Sampling International (SSI) cohort of 2,499 older adults (mean age 61 years)—81.1% and 61.4% of respondents, respectively, admitted to intentionally avoiding disclosure of at least one of seven fundamental categories of medically relevant information to their clinicians¹¹. An independent cross-sectional validation study of 2,725 outpatient participants (51.1% male, majority aged 18–39 years) corroborated these findings, revealing an overall nondisclosure prevalence of 82.6%¹².

EnlargeEnlarge figureSurvey results: 81.1% of younger adults, 61.4% of older adults and 82.6% of outpatients withheld medically relevant information, most often to avoid being judged or lectured.

A deeper examination of multivariable risk factors within these datasets exposes a critical clinical phenomenon termed the Vulnerability Paradox: the very patients who require the highest fidelity of clinical care due to complex pathology are statistically the most likely to compromise their diagnostic workup through nondisclosure¹¹. Regression modeling across both U.S. national cohorts reveals that worse self-rated health is independently associated with significantly higher rates of withholding information (MTurk $\text{OR} = 0.87$, $95\%\text{ CI } 0.76\text{–}0.99$; SSI $\text{OR} = 0.80$, $95\%\text{ CI } 0.72\text{–}0.88$, where lower self-rated health scores predict higher nondisclosure)¹¹. Similarly, female sex (MTurk $\text{OR} = 1.88$; SSI $\text{OR} = 1.38$) and younger age ($\text{OR} = 0.98$ per year of increasing age; 70.4% nondisclosure under age 40 vs. 29.6% over age 40 in outpatient replicates, $p = 0.0034$) strongly predict concealment¹¹. Additionally, 12.3% of U.S. patients report withholding clinical information specifically due to anxieties regarding the security or privacy of their electronic medical records¹³, while 27% of undocumented immigrants and 8% of legal immigrants avoid healthcare encounters due to immigration-related fears¹⁴.

To model how patient dishonesty generates chronic morbidity, clinical deception can be stratified into four distinct mechanistic pathways, each carrying a different probability of causing irreversible organ damage:

Forensic Biomarker Discrepancies in "Idiopathic" and "Cryptogenic" Cohorts

Because patients rarely confess to deception when chronic disease is diagnosed, the true causal burden must be inferred by examining clinical cohorts where a disease is initially labeled "idiopathic," "cryptogenic," or "refractory," and comparing patient self-reports against objective forensic biomarkers. Across internal medicine, a substantial fraction of severe chronic pathology lacks an immediately identifiable etiology: up to 50% of cardiomyopathies, 30%–40% of ischemic strokes, 25%–50% of adult fevers of unknown origin, 10%–28% of interstitial nephritis cases, 20% of end-stage chronic kidney disease (CKD), 8%–29% of chronic pancreatitis, and 5%–30% of liver cirrhosis are classified as idiopathic or cryptogenic²². While genetic variants account for a significant share of these cases—such as 50% of idiopathic CKD in Spanish registry analyses and 12%–57% of idiopathic chronic pancreatitis²³—modern biochemical assays reveal that a substantial proportion of the remaining idiopathic pool is driven by undisclosed patient behaviors.

EnlargeEnlarge figureForensic assays against self-report: PEth testing shows 66.3% of chronic liver disease patients misreporting alcohol, and urine LC-MS/MS shows 55.3% of apparent resistant hypertension patients not taking their prescribed drugs.

Steatotic Liver Disease, MetALD, and Cryptogenic Cirrhosis

Historically, between 5% and 30% of all cirrhosis cases have been designated as cryptogenic cirrhosis (CC) due to the absence of viral hepatitis markers, autoimmune antibodies, or self-reported heavy alcohol consumption²². While clinical characterization demonstrates that a majority of cryptogenic cirrhosis cases represent "burnt-out" metabolic dysfunction-associated steatohepatitis (MASH/NASH) associated with obesity and type 2 diabetes²⁴, occult alcohol consumption has persistently clouded diagnostic differentiation²⁵.

The clinical deployment of serum phosphatidylethanol (PEth)—an abnormal phospholipid formed exclusively in erythrocyte membranes in the presence of ethanol, exhibiting 98%–100% specificity and a detection window of up to 4 to 12 weeks—has quantified the exact magnitude of patient alcohol denial¹⁶. In a retrospective cohort of 279 chronic liver disease patients evaluated with PEth testing ($\ge 10\text{ ng/mL}$ cutoff), only 33.7% provided self-reports consistent with their biochemical profile, while 66.3% ($p < 0.001$) exhibited significant discrepancies¹⁶. Specifically, 57.7% of all patients actively underreported their alcohol consumption, and 19.7% with severe heavy drinking ($\text{PEth} > 200\text{ ng/mL}$) falsely reported only light consumption¹⁶. Most strikingly, the rate of covert alcohol underreporting was virtually identical between patients diagnosed with alcohol-related cirrhosis (58.0%) and those carrying a clinical diagnosis of "non-alcohol-related" cirrhosis (56.4%)¹⁶.

Even in highly controlled clinical trial and outpatient settings, covert alcohol intake is pervasive. In a multicenter prospective cohort of 2,870 patients screened for metabolic dysfunction-associated steatotic liver disease (MASLD) pharmacological trials—where significant alcohol intake is a strict exclusion criterion—systematic baseline testing revealed that 11% had $\text{PEth} \ge 20\text{ ng/mL}$, comprising 6% with moderate levels ($20\text{–}100\text{ ng/mL}$) and 5% with high levels ($\ge 100\text{ ng/mL}$), including 92 patients with $\text{PEth} \ge 200\text{ ng/mL}$²⁶. Similarly, in outpatient steatotic liver disease clinics, 16% of participants underreport alcohol intake when verified against a PEth threshold of $25\text{ ng/mL}$ ($\text{AUROC} = 0.81$ for discriminating MetALD from MASLD)²⁷, and 50% of patients claiming at least 4 weeks of abstinence test positive via PEth²⁸. Among 104 newly diagnosed alcohol-related liver disease (ALD) patients, where 30% presented with decompensated cirrhosis, 56% claimed complete abstinence at baseline assessment; however, PEth testing ($\le 0.05\text{ }\mu\text{mol/L}$ or $<35\text{ ng/mL}$) confirmed abstinence in only 37%, exposing active underreporting in 40% of the cohort²⁹.

This diagnostic misclassification carries severe longitudinal mortality consequences. Population-based analysis of 41,100 U.S. adults over 410,293 person-years of follow-up (2021–2023) demonstrates that relying on patient self-report yields an uncorrected prevalence of just 1.7% for ALD and 2.1% for metabolic and alcohol-associated liver disease (MetALD)³⁰. When adjusted for alcohol underreporting, true population prevalence more than doubles to 4.6% for ALD and nearly doubles to 4.1% for MetALD³⁰. Because premature mortality is 2.21-fold higher in ALD ($14.91\text{ per }1{,}000\text{ person-years}$) and 1.45-fold higher in MetALD ($8.74\text{ per }1{,}000\text{ person-years}$) compared to abstinent controls ($4.76\text{ per }1{,}000\text{ person-years}$), patient denial directly prevents combined cardiometabolic and addiction intervention during the reversible pre-cirrhotic window³⁰.

Pseudoresistant Hypertension and Accelerated Target-Organ Damage

Hypertension is the primary modifiable driver of chronic kidney disease—accounting for 85% of known-cause CKD cases alongside type 2 diabetes—as well as heart failure and cerebrovascular accidents¹⁵. Approximately 10% to 20% (and in some referral estimates up to 30%) of the global hypertensive population is classified as having apparent treatment-resistant hypertension (aTRH), defined as uncontrolled blood pressure despite prescription of three or more antihypertensive agents¹⁵. When a patient presents with persistent severe hypertension and verbally confirms medication adherence, clinicians diagnose "true resistant" or "refractory" hypertension, escalating polypharmacy or recommending invasive interventions such as radiofrequency renal denervation or carotid baroreceptor activation therapy¹⁵.

Forensic toxicology has revealed that the majority of apparent resistant hypertension is actually pseudoresistant hypertension induced by concealed medication nonadherence¹⁵. In a comprehensive meta-analysis of 25 studies encompassing 12,628 hypertensive patients, overall nonadherence was 45.2% ($95\%\text{ CI } 34.4\%\text{–}56.1\%$), but among patients with uncontrolled blood pressure, nonadherence reached 83.7%³¹. When self-report scales are replaced by liquid chromatography-tandem mass spectrometry (LC-MS/MS) screening of urine or serum for 43 cardiovascular drug metabolites in specialist hypertension centers ($n = 300$, median 4 prescribed antihypertensive drugs), 55.3% of patients claiming adherence are biochemically nonadherent³². Crucially, 20.0% of all evaluated resistant patients exhibit complete nonadherence, with zero prescribed antihypertensive medication detected in their urine³², while broader clinical reviews detect complete or partial nonadherence in up to 80% of apparent resistant cases³³.

Biochemical profiling of these deceptive nonadherent cohorts reveals a distinct clinical signature: compared to truly adherent resistant patients, nonadherent patients are significantly younger (median age 57 vs. 66 years; complete nonadherents median age 53 years), predominantly female (54%), prescribed a higher pill burden (especially dihydropyridine calcium channel blockers [66.3% vs. 33.7%] and diuretics [84% vs. 64%]), and exhibit significantly higher systolic ($181\text{ vs. }172\text{ mmHg}$) and diastolic ($100\text{ mmHg}$) blood pressures alongside preserved baseline eGFR ($76\text{ vs. }66\text{ mL/min/1.73 m}^2$)³². Because these younger patients conceal their nonadherence over years to avoid physician lectures, they endure unmitigated arterial pressure that silently progresses into irreversible hypertensive nephrosclerosis, left ventricular hypertrophy, and hemorrhagic or ischemic stroke.

Covert Herbal Nephrotoxicity, Supplement Hepatotoxicity, and Factitious Syndromes

A third major reservoir of deception-induced chronic disease arises from the undisclosed ingestion of biologically active compounds, ranging from over-the-counter herbal and dietary supplements (HDS) to surreptitious pharmaceuticals in factitious disorders. More than 50% of U.S. adults consume dietary supplements daily (rising to 64%–73.3% among chronic disease populations in international cohorts)³⁴, yet 24% of general outpatients and 20%–77% of oncology patients withhold complementary and alternative medicine (CAM) use from their physicians¹². Respondents cite anticipation of clinician disapproval, belief that "natural" products are irrelevant to western medicine, and lack of direct physician inquiry as primary reasons for concealment¹³.

This omission has profound chronic and fatal consequences in hepatology. Data from the NIH-funded U.S. Drug-Induced Liver Injury Network (DILIN) demonstrate that the proportion of all drug-induced liver injury attributable to herbal and dietary supplements surged nearly threefold, from 7% in 2004–2005 to 20% by 2013–2014, reaching 23.6% in 2026 retrospective cohorts ($n = 712$)³⁴. High-performance liquid chromatography (HPLC) audits by DILIN of 272 implicated supplements revealed a 51% mislabeling rate, where products contained undisclosed synthetic steroids, heavy metals, pesticides, or hepatotoxic botanicals such as green tea extract—strongly linked to the HLA-B*35:01 allele in 72%–90% of cases—and pyrrolizidine alkaloids such as Comfrey³⁵. Because patients conceal HDS use, diagnosis of HDS-induced liver injury (HILI) is delayed during the critical window when cessation could prevent necrosis. Consequently, HDS-related liver injury results in double the rate of severe hepatocellular injury compared to conventional prescription medications (29.2% vs. 14.5%, absolute risk difference 14.7%)³⁴, accounts for over 18% of all U.S. acute liver failure (ALF) cases³⁵, and leads to liver transplantation or death in 83% of HDS-ALF cases compared to 66% for prescription drug-induced ALF³⁶. While the FDA estimates 50,000 adverse events annually from HDS, predominantly involving hepatic and renal injury, fewer than 1% of adverse reactions are ever reported³⁶.

In nephrology, undisclosed consumption of weight-loss or traditional herbal remedies derived from Aristolochia and Asarum species causes aristolochic acid nephropathy (AAN, historically termed "Chinese herb nephropathy")¹⁷. Even after the 1990s Brussels slimming-clinic epidemic exposed aristolochic acid as a potent nephrotoxin and Class I human carcinogen, covert ingestion continues globally, causing rapidly progressive renal atrophy, extensive interstitial fibrosis, end-stage renal disease requiring dialysis or transplantation within 1 to 7 years, and a 30%–45% cumulative incidence of upper urinary tract transitional cell carcinoma¹⁷. When patients conceal herbal slimming pill use, early reversible Fanconi syndrome is missed, and the resulting renal failure is misclassified within the 10%–28% of interstitial nephritis or 20% of CKD cases of unknown origin²².

At the severe psychiatric end of the spectrum, Factitious Disorder Imposed on Self (Munchausen syndrome) is estimated to occur in 0.5% to 2.0% of all general internal medicine hospital admissions and 0.6% to 3.0% of psychiatric consultations²⁰. Unlike malingerers who pursue external financial or legal gain, factitious patients consciously induce or falsify illness to fulfill an unconscious psychological need to assume the sick role³⁷. When confronted with forensic evidence, 77% respond with adamant denial and transfer care to a new hospital²¹. The most prevalent chronic manifestations involve surreptitious laxative abuse—which is also widespread among eating disorder and middle-aged cohorts—and covert diuretic abuse¹⁹. Covert ingestion of stimulant laxatives such as senna presents as chronic idiopathic diarrhea, malabsorption, or refractory inflammatory bowel disease¹⁹. Diagnostic delay leads to chronic volume depletion, secondary hyperaldosteronism triggering "pseudo-idiopathic edema" upon withdrawal, colonic melanosis coli, and permanent hypokalemic nephropathy and chronic kidney disease¹⁹. Similarly, covert diuretic abuse or self-induced vomiting mimics genetic renal tubulopathies, specifically pseudo-Bartter syndrome, which is distinguished only when clinicians order urinary chloride assays—revealing low urinary chloride in covert vomiting or diuretic withdrawal versus high levels in true Bartter syndrome—or urinary diuretic toxicology screens¹⁹. Covert exogenous insulin or thyroxine administration likewise simulates insulinoma or hyperthyroidism, frequently triggering unnecessary pancreatic resections or thyroid ablations before C-peptide or thyroglobulin assays expose the deception¹⁹.

Oncological Stage Migration from Symptom Concealment

In oncology, patient deception frequently manifests as symptom denial, concealment of a growing mass due to embarrassment or fear of mastectomy and chemotherapy, and secret reliance on spiritual or alternative healing before presenting or returning to conventional medical care¹⁸. A clinical cohort study of breast cancer patients ($n = 146$) demonstrated that 42.5% ($n = 62$) engaged in prolonged secondary patient delay after initial symptom recognition or diagnosis, with a mean delay of $27.7 \pm 9.5\text{ months}$ among the 48.4% who secretly pursued complementary or alternative therapies and $15.6 \pm 4.9\text{ months}$ among the 17.8% driven by fear of surgery or chemotherapy¹⁸. During this self-imposed delay, mean tumor size nearly doubled from $8.2\text{ cm}$ to $15.4\text{ cm}$, and stage migration was catastrophic: the proportion of patients with early-stage (Stage I/II) curable disease collapsed from 33.8% at initial presentation to 3.2% prior to treatment, while advanced or metastatic disease (Stage III/IV) surged from 66.1% to 96.8%¹⁸. Similarly, in oral cancer cohorts where fear, denial, and alternative treatment pursuit are prevalent, 90.0% of patients present at advanced stages (67.3% Stage IV and 22.7% Stage III vs. only 3.6% Stage I)³⁸. Meta-analytic survival modeling confirms that every single month of delay in cancer treatment initiation is associated with an estimated 10% increase in mortality¹⁴, converting curable localized neoplasms into chronic, palliative, or fatal malignancies.

Probabilistic Fermi Modeling of U.S. Chronic Disease Burden

Because no single surveillance registry captures deception-induced chronic morbidity, estimating the national case burden requires a dual-pathway probabilistic Fermi model combining a Top-Down Diagnostic Error Attribution Model with a Bottom-Up Disease-Specific Etiological Fraction Model across three confidence tiers⁴². The Conservative Lower Bound (Tier 1, $90\%$ Confidence Floor) is restricted to cases where biochemical or clinical evidence confirms direct, active patient falsification or omission as the primary proximate cause of irreversible organ failure or stage migration⁴². The Moderate Central Estimate (Tier 2, $75\%$ Plausible Best Estimate) incorporates standard epidemiological attributable fractions of biochemically verified underreporting—such as PEth-confirmed occult alcohol and LC-MS/MS-confirmed antihypertensive nonadherence—across chronic disease incidence⁴². Finally, the Upper-Bound Sensitivity Tier (Tier 3, $50\%$ Expanded Cryptogenic Allocation) includes broader allocations of idiopathic and cryptogenic disease pools alongside secondary patient delays where nondisclosure acts as a decisive co-factor accelerating subclinical disease into permanent morbidity⁴².

Mathematical Formulation

Pathway A: Top-Down Severe Permanent Disability Model

Starting from the national burden of serious diagnostic harm established by Newman-Toker et al., approximately $H_{\text{total}} = 795{,}000$ Americans experience death or permanent disability from diagnostic error annually, of which non-fatal permanent disability accounts for $D_{\text{perm}} \approx 424{,}000\text{ cases/year}$ ($\sim 53.3\%$)². Let $P(\text{Enc}) = 0.789$ represent the proportion of diagnostic errors involving a breakdown in the patient-practitioner encounter, $P(\text{Hist}\vert{}\text{Enc}) = 0.563$ represent history-taking defects, and $P(\text{Pat}) = 0.163$ represent explicit patient-related factors in primary care⁵. Defining $\alpha_k \in \{0.02, 0.05, 0.10\}$ as the tier-specific attribution coefficient representing the fraction of catastrophic diagnostic disabilities where active patient deception or nondisclosure was the primary root cause:

$$I_{\text{top-down}, k} = D_{\text{perm}} \times \alpha_k$$

This yields an annual incidence of catastrophic, acute diagnostic permanent disability caused by patient deception of $8{,}480\text{ cases/year}$ (Conservative), $21{,}200\text{ cases/year}$ (Moderate), and $42{,}400\text{ cases/year}$ (Upper-Bound)⁴².

Pathway B: Bottom-Up Disease-Specific Incidence & Prevalence Model

Top-down malpractice and hospital trigger-tool audits systematically undercount chronic diseases because they capture only discrete, acute diagnostic failures—such as a missed myocardial infarction or stroke—while ignoring longitudinal outpatient pathologies where a physician makes a correct initial diagnosis (such as hypertension or steatotic liver disease) but is deceived regarding adherence or toxin exposure over subsequent years³². To capture the true chronic burden, annual U.S. incident cases ($I_{\text{bottom-up}, k}$) are summed across six major clinical domains $i \in \{1 \dots 6\}$, where $N_i$ is the annual U.S. incidence of the chronic condition (or size of the cryptogenic/resistant pool), $\theta_{i,k}$ is the prevalence of patient deception or concealment in domain $i$, and $\gamma_{i,k}$ is the annual probability of irreversible chronic progression attributable to the delay or mismanagement:

$$I_{\text{bottom-up}, k} = \sum_{i=1}^{6} \left( N_i \times \theta_{i,k} \times \gamma_{i,k} \right)$$

Assuming a tier-weighted mean chronic disease survival duration $L_k \in \{10, 12, 15\}\text{ years}$, the cumulative U.S. prevalent population ($P_{\text{total}, k}$) currently living with a chronic health condition induced by prior clinical deception is modeled via steady-state epidemiological equilibrium:

$$P_{\text{total}, k} = I_{\text{bottom-up}, k} \times L_k$$

EnlargeEnlarge figureFermi model output: about 158,000 new U.S. cases a year (64,000 to 325,000 across tiers), led by pseudoresistant hypertension and cancer stage migration, shown beside the idiopathic disease pools that hide them.

Domain-by-Domain Probabilistic Breakdown

The table below synthesizes the quantitative parameters, epidemiological base populations, and resulting case estimates across the three confidence tiers⁴²:

Analytical Synthesis of the Model Outputs

Reconciling the Top-Down and Bottom-Up probabilistic models reveals a 7.5-fold divergence between acute malpractice audits and longitudinal chronic disease burden. The Top-Down model identifies $21{,}200\text{ cases/year}$ (range: $8{,}480\text{–}42{,}400$) of severe permanent disability, whereas the Bottom-Up model identifies $158{,}000\text{ cases/year}$ (range: $64{,}000\text{–}325{,}000$)⁴². This disparity occurs because top-down diagnostic safety studies rely on malpractice claims and hospital adverse-event triggers that predominantly flag sudden, catastrophic misdiagnoses, such as a missed pulmonary embolism, aortic dissection, or subarachnoid hemorrhage⁴⁴. Conversely, two-thirds of the actual chronic disease burden caused by patient deception—specifically cardiovascular and renal damage from pseudoresistant hypertension ($41.1\%$) and oncological stage migration from pre-presentation symptom concealment ($25.3\%$)—occurs outside the boundaries of traditional diagnostic error definitions because the clinician either never saw the patient during the delay interval or correctly diagnosed the baseline condition while being deceived about treatment compliance¹⁵.

Furthermore, in both pseudoresistant hypertension and factitious disorder, patient deception does not merely delay treatment; it actively induces iatrogenic chronic morbidity¹⁵. When a patient with uncontrolled blood pressure conceals nonadherence, the clinician escalates dosages or adds third-, fourth-, and fifth-line agents³². If the patient subsequently ingests all prescribed medications simultaneously, such as immediately prior to a clinic visit, profound hypotension, syncope, and acute-on-chronic renal ischemia ensue. Similarly, when patients with covert laxative abuse or factitious illness conceal their ingestions, they undergo repetitive endoscopic biopsies, exploratory laparotomies, colectomies, and immunosuppressive regimens for presumed refractory autoimmune disease, resulting in permanent surgical disability¹⁹.

Once a patient's deceptive history leads to an incorrect initial diagnostic label—such as pure metabolic MASLD instead of MetALD or ALD, or stress and anxiety instead of stimulant-induced vasospasm—clinical anchoring and context errors lock the trajectory in place⁴. Randomized clinical simulation studies demonstrate that when clinicians inherit a wrong a priori diagnosis in the medical chart, diagnostic error rates increase substantially even when clinicians are given 20% more time with the patient, as they ask the exact same limited number of history questions (median 7 questions, $\text{IQR } 5\text{–}10$, $p = 0.97$) and fail to order disconfirming tests⁴⁵. Copy-and-paste propagation of unverified social histories in ambulatory EHRs further entrenches this false baseline across subsequent specialist referrals⁸.

Clinical and Systemic Interventions to Mitigate Deception-Induced Morbidity

Reducing the estimated $158{,}000$ annual incident cases of chronic morbidity caused by patient nondisclosure requires shifting the diagnostic paradigm from passive reliance on verbal self-report toward structural biochemical verification, psychological safety, and algorithmic anomaly detection.

Routine Integration of Objective Forensic Biomarkers

Clinical guidelines in hepatology and cardiology increasingly recognize that verbal history-taking is statistically insufficient to exclude alcohol toxicity or medication nonadherence³². Rather than reserving phosphatidylethanol testing for liver transplant evaluations, routine PEth screening ($\ge 20\text{–}35\text{ ng/mL}$ threshold) can be integrated into the baseline workup of all patients presenting with steatotic liver disease (MASLD), cryptogenic cirrhosis, idiopathic chronic pancreatitis, and idiopathic axonal polyneuropathy³⁹. Combining PEth with multivariable laboratory ratios—specifically noting that covert alcohol consumers in MASLD cohorts exhibit significantly elevated $\gamma$-glutamyltransferase ($\text{aOR} = 1.04\text{ per }10\text{ U/L}$, $p < 0.001$) alongside paradoxically lower HbA1c ($\text{aOR} = 0.68$, $p < 0.001$) and indeterminate FIB-4 scores²⁶—enables clinicians to identify MetALD early and initiate concurrent GLP-1 receptor agonist or addiction pharmacotherapy, which reduces 1-year alcohol relapse by 45% ($\text{IRR} = 0.55$, $p < 0.01$)³⁹.

In cardiovascular and renal medicine, performing urinary or serum LC-MS/MS adherence screening in patients meeting criteria for apparent treatment-resistant hypertension prior to adding fourth-line mineralocorticoid receptor antagonists or referring for invasive renal denervation unmasks the 55.3% to 80% with pseudoresistance¹⁵. Identifying nonadherence allows clinicians to simplify complex regimens via single-pill fixed-dose combinations, directly targeting pill burden as the primary modifiable driver of concealment³². Similarly, early stool osmolality and urinary electrolyte or diuretic screening in unexplained hypokalemia or chronic diarrhea prevents years of futile workups for pseudo-Bartter syndrome or factitious enteropathy¹⁹.

Asynchronous Digital Elicitation and Non-Judgmental Communication

Because 64.1% to 81.8% of patients withhold information specifically to avoid being judged or lectured during face-to-face encounters¹¹, modifying the medium of history collection directly alters disclosure probabilities. Deploying asynchronous, impersonal digital intake instruments prior to the clinical visit significantly increases patient willingness to report sensitive behaviors, including substance use, sensitive behavioral risk factors, medication nonadherence, and alternative supplement ingestion⁴⁶. Within the clinical encounter, replacing interrogative questioning regarding daily medication compliance with normalizing, blame-free inquiry that acknowledges side effects or cost constraints dismantles the impression-management barrier¹¹. Furthermore, explicitly inviting patients to co-review their Open Notes in plain, person-first language builds therapeutic trust and reduces the perception of clinical stigmatization⁴⁷.

Predictive Analytics and EHR Discordance Triggers

Finally, health systems can bypass verbal omissions by deploying machine learning ensembles and automated electronic trigger tools across harmonized EHR data⁴⁸. Automated algorithms that cross-reference pharmacy dispensation gaps, laboratory biomarker trajectories, and repeat emergency or urgent care visits can flag patients experiencing diagnostic inertia or covert nonadherence before end-organ damage becomes irreversible⁴⁹. Meta-analyses of 127 clinical validation studies (2020–2025) demonstrate that integrating predictive analytics into chronic disease workflows reduces diagnostic delays by 35% to 60% across chronic conditions—exemplified by a 42% reduction in time-to-diagnosis for autoimmune conditions and a 28% reduction in unnecessary specialist referrals in integrated health systems—while reducing U.S. healthcare expenditures by an estimated $164 billion annually⁴⁹.

Additional sources consulted

• Burden of Harm from Diagnostic Error Still High | Clinician.com, https://www.clinician.com/articles/burden-of-harm-from-diagnostic-error-still-high
• Burden of serious harms from diagnostic error in the USA. | PSNet, https://psnet.ahrq.gov/issue/burden-serious-harms-diagnostic-error-usa
• Prevalence and characterisation of diagnostic error among 7-day all, https://qualitysafety.bmj.com/content/29/12/971
• Documentation-related diagnostic safety concerns in primary care, https://qualitysafety.bmj.com/content/early/2026/09/15/bmjqs-2026-020701
• Types and Origins of Diagnostic Errors in Primary Care Settings - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC3690001/
• 21st Century Cures Act - AACAP, https://www.aacap.org/App_Themes/AACAP/docs/clinical_practice_center/business_of_practice/emr/21st-Century-Open-Notes-Intro-FAQs.pdf
• 21st Century Cures Act and Open Notes : r/medicine - Reddit, https://www.reddit.com/r/medicine/comments/jodeu9/21st_century_cures_act_and_open_notes/
• Open Notes Become Law: A Challenge for Mental Health Practice, https://psychiatryonline.org/doi/10.1176/appi.ps.202000782
• Open Notes in Healthcare: The Good, the Bad, and the Ugly of the, https://www.acc.org/membership/join-us/benefits/additional-member-only-benefits/acc-and-the-doctors-company/the-doctors-company-updates/2021/08/20/13/55/open-notes-in-healthcare-the-good-the-bad-and-the-ugly-of-the-cures-act
• An innovative method to track stigmatizing language in addiction, https://www.recoveryanswers.org/research-post/innovative-method-track-stigmatizing-language-addiction-treatment-clinical-notes/
• By the numbers: Honesty at the doctor's office, https://www.apa.org/monitor/2019/03/numbers
• Up to 81% of patients lie to their doctors—and there's one big, https://www.advisory.com/daily-briefing/2018/12/10/lying-patients
• 25: Factitious Disorders and Malingering | Clinical Gate, https://clinicalgate.com/2015/05/24/25-factitious-disorders-and-malingering/
• (PDF) Laxative Abuse: Epidemiology, Diagnosis and Management, https://www.researchgate.net/publication/45507016_Laxative_Abuse_Epidemiology_Diagnosis_and_Management
• Cryptogenic cirrhosis in the region where obesity is not prevalent, https://pdfs.semanticscholar.org/ebc7/716caeec8f3b598a001a95c239b9acc1540f.pdf
• Outcomes of curative treatment for hepatocellular... : Hepatology, https://www-ovid-com.ezproxy.uky.edu/jnls/hep/fulltext/10.1002/hep.25536~outcomes-of-curative-treatment-for-hepatocellular-cancer-in
• Liver transplantation of patients with cryptogenic cirrhosis - PubMed, https://pubmed.ncbi.nlm.nih.gov/20030578/
• Detection of Potential Metabolic and Alcohol-Associated Liver, https://pubmed.ncbi.nlm.nih.gov/42641902/
• Evolution of Chronic Kidney Disease in Different Regions of the World, https://www.mdpi.com/2077-0383/14/12/4144
• (PDF) A Dilute-and-Shoot LC-MS/MS Method for Screening of 43, https://www.researchgate.net/publication/350783483_A_Dilute-and-Shoot_LC-MSMS_Method_for_Screening_of_43_Cardiovascular_Drugs_in_Human_Urine
• [Aristolochic acid nephropathy ("Chinese herb ... - PubMed, https://pubmed.ncbi.nlm.nih.gov/26515658/
• Aristolochic acid nephropathy: variation in presentation and prognosis, https://academic.oup.com/ndt/article-abstract/27/1/292/1928919
• Reversible Fanconi syndrome after ingestion of a Chinese herbal, https://academic.oup.com/ndt/article-abstract/16/2/400/1849722
• Malingering and factitious disorder - Practical Neurology, https://pn.bmj.com/content/practneurol/early/2018/11/13/practneurol-2018-001950.full.pdf
• Factitious disease: clinical lessons from case studies at Baylor, https://pmc.ncbi.nlm.nih.gov/articles/PMC1484524/
• Presentation intervals and the impact of delay on breast cancer, https://pmc.ncbi.nlm.nih.gov/articles/PMC7304119/
• Delay in diagnosis and treatment of patients with oral cancer, https://ecancer.org/en/journal/article/2181-delay-in-diagnosis-and-treatment-of-patients-with-oral-cancer-seeking-treatment-in-a-public-hospital-in-india-a-cross-sectional-study
• Estimated prevalence of each of the causes of pseudoresistant, https://www.researchgate.net/figure/Estimated-prevalence-of-each-of-the-causes-of-pseudoresistant-hypertension-BP-indicates_fig1_328663718
• Clinical Characteristics and Prognosis of Idiopathic Acute Pancreatitis, https://pmc.ncbi.nlm.nih.gov/articles/PMC8284986/
• Primary care time squeeze explains errors in diagnosis, https://amednews.com/article/20130311/profession/130319973/2/
• Diagnostic Error in Surgery and Surgical Services - Nurse Key, https://nursekey.com/diagnostic-error-in-surgery-and-surgical-services/
• Copy and Paste in the Medical Record: A Top EHR Danger - crico, https://www.rmf.harvard.edu/Podcasts/2023/Copy-and-Paste-Risk
• Dominant T-cell clones of unknown significance in patients with, https://www.neurology.org/doi/10.1212/WNL.51.2.384
• Why Do Patients Withhold Information? | MedPage Today, https://www.medpagetoday.com/publichealthpolicy/generalprofessionalissues/76631
• Open Notes for Mental Health Clinicians - OpenNotes.org, https://www.opennotes.org/mental-health-professionals/
• Types and Origins of Diagnostic Errors in Primary Care Settings, https://www.ajustnhs.com/wp-content/uploads/2012/10/diag-errors-JAMA-2013.pdf
• Decoding Diagnostic Delay in COPD: An Integrative Analysis ... - MDPI, https://www.mdpi.com/2075-4418/15/17/2209

Works cited

1. Pat Croskerry, Karen Cosby, Mark L. Graber, Hardeep Singh | PDF, https://www.scribd.com/document/697295541/Pat-Croskerry-Karen-Cosby-Mark-L-Graber-Hardeep-Singh-Diagnosis-Interpreting-the-Shadows-CRC-Press-2017 ↑

2. Connecting the Dots - crico, https://www.rmf.harvard.edu/News-and-Blog/Newsletter-Home/News/2022/SPS-September-Connecting-the-Dots ↑ 2 3

3. Common contributing factors of diagnostic error: A retrospective, https://pmc.ncbi.nlm.nih.gov/articles/PMC11503095/ ↑ 2 3

4. Diagnostic Error in Acute Care Advisory - Patient Safety Authority, https://patientsafety.pa.gov/ADVISORIES/Pages/201009_76.aspx ↑ 2

5. Types and Origins of Diagnostic Errors in Primary Care Settings, https://www.researchgate.net/publication/235729759_Types_and_Origins_of_Diagnostic_Errors_in_Primary_Care_Settings ↑ 2 3

6. Reducing Diagnostic Error: Measurement Considerations, https://digitalassets.jointcommission.org/api/public/content/cf421e529f274db990ed96358d5d471c?v=adceae7d ↑

7. Open Notes: The Pros and Cons of Patients Having Access to Your, https://www.medcentral.com/biz-policy/open-notes-the-pros-and-cons-of-patients-having-access-to-your-charts ↑

8. Opening Your Notes: Patient Care Recommendations - crico, https://www.rmf.harvard.edu/Risk-Prevention-and-Education/Article-Catalog-Page/Articles/2021/Opening-Notes-Patient-Care-Recommendations ↑ 2 3

9. Medication Noncompliance - ICD-10 Documentation Guidelines, https://icdcodes.ai/diagnosis/medication-noncompliance/documentation ↑ 2 3

10. 2027 ICD-10-CM Diagnosis Code Z91.19, https://www.icd10data.com/ICD10CM/Codes/Z00-Z99/Z77-Z99/Z91-/Z91.19 ↑

11. Prevalence of and Factors Associated With Patient Nondisclosure of, https://pmc.ncbi.nlm.nih.gov/articles/PMC6324389/ ↑ 2 3 4 5 6 7 8

12. Prevalence, Reasons and Determinants of Patients' Nondisclosure, https://www.tandfonline.com/doi/full/10.2147/PPA.S347796 ↑ 2 3 4 5 6 7 8 9 10

13. (PDF) Prevalence of and Factors Associated With Patient, https://www.researchgate.net/publication/329328709_Prevalence_of_and_Factors_Associated_With_Patient_Nondisclosure_of_Medically_Relevant_Information_to_Clinicians ↑ 2 3 4

14. Comparing cancer stage at diagnosis between migrants and non, https://www.researchgate.net/publication/385771862_Comparing_cancer_stage_at_diagnosis_between_migrants_and_non-migrants_a_meta-analysis ↑ 2 3 4

15. When blood pressure refuses to budge: exploring the complexity of, https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2023.1211199/full ↑ 2 3 4 5 6 7 8 9 10 11

16. You can't handle the truth! Comparing serum phosphatidylethanol to, https://pubmed.ncbi.nlm.nih.gov/38431483/ ↑ 2 3 4 5 6 7 8

17. Herbal Nephropathy: The Risks of Aristolochic Acid, https://esmed.org/herbal-nephropathy-the-risks-of-aristolochic-acid/ ↑ 2 3 4

18. Patient delay in initiating treatment after breast cancer diagnosis, https://jhsronline.com/patient-delay-in-initiating-treatment-after-breast-cancer-diagnosis-a-cause-for-concern/ ↑ 2 3 4

19. Factitious disorder imposed on self - Wikipedia, https://en.wikipedia.org/wiki/Factitious_disorder_imposed_on_self ↑ 2 3 4 5 6 7 8 9 10

20. Factitious Disorder in the Context of Abuse in an Adolescent, https://www.psychiatrist.com/pcc/factitious-disorder-abuse-adolescent-multidisciplinary-approach/ ↑ 2

21. Day # 123: Factitious Disorder and Malingering - Bullet Psych, https://www.bulletpsych.com/post/day-123-factitious-disorder-and-malingering ↑ 2

22. Diseases with idiopathic etiology - - Caring Medical, https://caringmedical.com/diseases-with-idiopathic-etiology/ ↑ 2 3 4 5 6 7 8

23. Health in Code helps reveal that 50% of chronic kidney diseases of, https://healthincode.com/en/chronic-kidney-diseases-unknown-origin-genetic/ ↑

24. Cryptogenic Cirrhosis: Clinical Characterization and Risk Factors for, https://www.hepatitiscentral.com/hepatitis-c/cirrhosis/cryptogenic/cirrhosis/ ↑

25. Clinical features and natural history of cryptogenic cirrhosis ... - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC5330831/ ↑ 2

26. Alcohol Biomarker Identified Potential MetALD in MASLD - EMJ, https://www.emjreviews.com/hepatology/news/peth-identified-possible-metald-in-masld-emj/ ↑ 2

27. The global burden of metabolic and alcohol-associated liver disease, https://journals.lww.com/02009842-202610010-00008 ↑

28. Phosphatidylethanol in patients with liver diseases of different, https://ww2.uthscsa.edu/artt/addictionjc/2022-02-08-aboutara.pdf ↑ 2

29. Changes in alcohol use following a diagnosis of alcohol-related liver, https://researchprofiles.ku.dk/files/565723734/1-s2.0-S2589555926002065-main.pdf ↑

30. New findings expose a critical blind spot in liver disease classification, https://news.gastro.org/issues/2026/march/new-findings-expose-a-critical-blind-spot-in-liver-disease-classification/ ↑ 2 3

31. Nonadherence to antihypertensive drugs: A systematic review and, https://pmc.ncbi.nlm.nih.gov/articles/PMC5287944/ ↑ 2

32. Nonadherence to antihypertensive medications is related to pill, https://warwick.ac.uk/fac/sci/med/staff/cappuccio/publications/j_hypert_2020_adherence.pdf ↑ 2 3 4 5 6 7 8 9 10

33. Definition, risk factors, and evaluation of resistant hypertension, https://doctorabad.com/uptodate/d/topic.htm?path=definition-risk-factors-and-evaluation-of-resistant-hypertension ↑

34. Induced Liver Injury - Semantic Scholar, https://pdfs.semanticscholar.org/8b30/550981906813f4ea405000d5a74bc11f9482.pdf ↑ 2 3 4 5 6

35. A comprehensive update in herbal and dietary supplement–induced, https://pmc.ncbi.nlm.nih.gov/articles/PMC11191983/ ↑ 2 3

36. Hidden Dangers: Herbal and Dietary Supplement Induced ... - MDPI, https://www.mdpi.com/2673-4389/3/4/41 ↑ 2

37. Current, https://cdn.mdedge.com/files/s3fs-public/Document/September-2017/0202_Factitious.pdf ↑

38. Factors Associated with Delay from Diagnosis to Treatment Initiation, https://www.jpes.org.pk/index.php/jpes/article/download/83/62/740 ↑

39. Correlation of PEth levels with self‐reported alcohol use, AUDIT, https://www.researchgate.net/figure/Correlation-of-PEth-levels-with-self-reported-alcohol-use-AUDIT-score-and-indirect_fig3_388122536 ↑ 2 3

40. Pseudoresistant hypertension due to poor medication adherence, https://www.researchgate.net/publication/259916608_Pseudoresistant_hypertension_due_to_poor_medication_adherence ↑

41. Why it's important to tell the doctor the truth - Don't waste, https://www.nonsprecare.it/en/tell-the-doctor-the-truth ↑ 2

42. unknown_url ↑ 2 3 4 5 6 7 8 9 10

43. Idiopathic chronic pancreatitis: clinical highlights - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC13110326/ ↑ 2 3

44. The incidence of diagnostic error in medicine - ResearchGate, https://www.researchgate.net/publication/239077086_The_incidence_of_diagnostic_error_in_medicine ↑

45. Diagnostic Errors Induced by a Wrong a Priori Diagnosis - MDPI, https://www.mdpi.com/2077-0383/10/4/826 ↑

46. Most Patients Have Held Back the Truth From Doctors, JAMA, https://www.ajmc.com/view/most-patients-have-held-back-the-truth-from-doctors-jama-results-show ↑

47. Guidelines for Patient-Centered Documentation in the Era of Open, https://pmc.ncbi.nlm.nih.gov/articles/PMC11791454/ ↑

48. Overview of Diagnostic Error in Health Care - NCBI - NIH, https://www.ncbi.nlm.nih.gov/books/NBK338594/ ↑

49. Reducing Diagnostic Delays In Chronic Illnesses Using Predictive, https://www.researchgate.net/publication/394857561_Reducing_Diagnostic_Delays_In_Chronic_Illnesses_Using_Predictive_Analytics_A_Framework_For_Healthcare_Transformation_In_The_United_States ↑ 2